Practical Neurology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Practical Neurology 2005;5:18-27; doi:10.1111/j.1474-7766.2005.00280.x
Copyright © 2005 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hilton-Jones, D.
Right arrow Articles by Palace, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hilton-Jones, D.
Right arrow Articles by Palace, J.

Reviews

The Management of Myasthenia Gravis

David Hilton-Jones, Jackie Palace

Consultant Neurologists, Myasthenia Gravis Association Myasthenia Centre, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE; E-mail: david.hilton-jones{at}clinical-neurology.oxford.ac.uk

EXTRACT

INTRODUCTION

This is a pragmatic guide to the management of myasthenia gravis. We will assume the diagnosis is correct (Hilton-Jones 2002) and the reader understands the pathogenesis of the disorder (Newsom-Davis & Beeson 2001), and we will deal only with pharmacological and surgical management. The mode of action of different pharmacological treatments will not be discussed, but their adverse effects will be.

At the time of diagnosis, time must be set aside to adequately explain to the patient the nature of the disease and its management. The treatment strategy, the likely time-course of response, the long-term prognosis, potential complications of therapy, and the undoubted uncertainties about some areas of ‘best practice’ must all be discussed – this is clearly more difficult if the clinician sees relatively few cases of myasthenia, but is nonetheless crucial in optimizing patient adherence to therapy, and so outcome. Many countries have a patient support group–e.g. ...

[PDF of this article]


This article has been cited by other articles:


Home page
PNHome page
D Hilton-Jones
When the patient fails to respond to treatment: myasthenia gravis
Practical Neurology, November 1, 2007; 7(6): 405 - 411.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.